Media

Lilotomab pre-dosing of NHL patients before Betalutin® therapy lowers haematological toxicity with no reduction in the tumor absorbed radiation dose

Single stage surgical procedure achieves 96% infection eradication rate

GenSight Biologics receives Orphan Drug Designation and Advanced Therapy Medicinal Product classification in Europe for GS030 in Retinitis Pigmentosa

Positive safety and tolerability profile of CER-001 presented at the European Society of Cardiology (ESC) Congress 2016

Completion of patient enrolment in the CARAT study – meeting the clinical schedule

NORDIC NANOVECTOR ASA – RESULTS FOR SECOND QUARTER AND HALF YEAR 2016

RSPR Pharma hires Paul de Potocki as Chief Business Officer

WILSON THERAPEUTICS AB (PUBL) INTERIM REPORT JANUARY 1 – JUNE 30, 2016

Nordic Nanovector completes recruitment of the first cohorts of Arm 3 and Arm 4 of expanded Phase 1/2 study of Betalutin® in NHL patients